UNSPSC 51241131: Brimonidine tartrate

This classification denotes an alpha-adrenergic agonist with the molecular formula C11H10BrN5.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4S9CL2DY2H, chemically known as 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)- (9ci) but generally known as brimonidine tartrate, which bears US NIH Compound Identifier 2435. European Medicines Agency schedules Brimonidine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13122MIG.

Most nations schedule brimonidine tartrate under HS 29332990 and SITC 51573. As of Q4 2014, BRIMONIDINE TARTRATE remains the US FDA Preferred Term for this commodity. Brimonidine tartrate bears US NLM identifiers UMLS ID C0077768 and NCI Concept Code C47419. SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O.

UNSPSC 51241131 Brimonidine tartrate is a Commodity code covering ophthalmic pharmaceutical products sold through state and local cooperative purchasing agreements. State and local governments procure brimonidine tartrate and related generic pharmaceuticals primarily through multistate cooperative purchasing vehicles rather than individual agency solicitations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code, managing contracts that distribute products across participating state and local government facilities across multiple states including Oregon. Work solicited includes manufacturers' supply agreements for generic and branded pharmaceuticals meeting FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements, with products distributed through authorized pharmaceutical wholesalers.

MMCAP's most recent RFP, issued January 20, 2026 with proposals due March 26, 2026, seeks manufacturers for generic multi-source pharmaceuticals and OTC products to support state and local government healthcare facilities. The procurement requires vendor compliance with comprehensive product documentation including National Drug Codes, SKUs, UPCs, and manufacturing locations; maintenance of contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC); insurance coverage including $5 million commercial general liability and $2 million network security and privacy liability; and acceptance of a 3 percent administrative fee on all contract purchases. Evaluation weights heavily price competitiveness at 75 percent, with smaller weights on fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format requirements (5 percent). The resulting contracts are effective July 1, 2026, with a two-year term for new responders and optional extensions at MMCAP's discretion through June 30, 2028.